How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD-Reference-Cited by-同舟云学术

How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD

Published:2022-03-21 Issue:1 Volume:25 Page:356-366
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Wang Luying¹^ORCID,Gu Weili²,Zhang Xiao¹,Fu Shihui¹,Zhang Donger¹,Guan Xin¹,Li Hongchao¹,Ma Aixia¹

Affiliation:

1. School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China

2. The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2043633

Reference38 articles.

1. Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action

2. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study

3. Gold. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2022 report); 2021. Available from: https://goldcopd.org/2022-gold-reports-2/

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing Glycopyrronium/Formoterol Combination Therapy With Monotherapy in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD): A Narrative Review;Cureus;2024-04-20